Cannabix Detects Cocaine and Metabolite in Breath Samples
Event summary
- Cannabix Technologies detected cocaine and benzoylecgonine in human breath samples using its Marijuana Breath Test (MBT).
- The detection was confirmed by Omega Laboratories via liquid chromatography-mass spectrometry (LC-MS).
- This breakthrough expands potential applications beyond THC to multi-drug testing for workplace safety, law enforcement, and other markets.
- Cannabix CEO Rav Mlait highlighted the technical challenge of measuring low-concentration compounds in breath.
The big picture
Cannabix's ability to detect cocaine and its metabolite in breath samples represents a significant technical milestone, potentially broadening the applicability of its MBT system. This development aligns with growing demand for non-invasive, real-time drug testing solutions in workplace safety and law enforcement sectors. The company now faces the challenge of scaling this capability while navigating regulatory frameworks for multi-drug breath testing.
What we're watching
- Market Expansion
- How Cannabix will leverage this detection capability to penetrate new markets beyond cannabis testing.
- Regulatory Approval
- Whether the expanded drug-detection capabilities will face additional regulatory hurdles for commercial deployment.
- Technical Validation
- The pace at which Cannabix can validate and standardize this detection method across different drug compounds.